Comparative Pharmacology
Head-to-head clinical analysis: LUPRON versus TRIPTODUR KIT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LUPRON versus TRIPTODUR KIT.
LUPRON vs TRIPTODUR KIT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Gonadotropin-releasing hormone (GnRH) agonist. Chronic administration suppresses pituitary gonadotropin secretion, leading to decreased testosterone and estradiol levels.
Gonadotropin-releasing hormone (GnRH) agonist; continuous administration suppresses pituitary gonadotropin (LH and FSH) secretion, leading to decreased testosterone production in males and estrogen production in females.
3.75 mg intramuscularly once monthly or 11.25 mg intramuscularly once every 3 months. For endometriosis, 3.75 mg intramuscularly monthly for up to 6 months. For central precocious puberty, 0.3 mg/kg intramuscularly every 28 days.
3.75 mg intramuscularly once every 28 days.
None Documented
None Documented
Terminal half-life approximately 3 hours after subcutaneous administration; in patients with renal impairment, half-life may be prolonged
Terminal elimination half-life is 28-35 hours in healthy adults, allowing for a 4-week dosing interval. In patients with renal impairment, half-life is prolonged.
Renal (primarily as metabolites), <5% unchanged; fecal ~5%
Renal (approximately 50% as unchanged drug and metabolites); biliary/fecal (approximately 20-30%); the remainder is metabolized.
Category C
Category C
GnRH Agonist
GnRH Agonist